The University of Rochester Medical Center announced today its participation in a clinical trial sponsored by the National Institute of Health to evaluate the safety and effectiveness of antiviral drug remdesivir for adult patients hospitalized with COVID-19.
Ann Falsey M.D. and Angela Branche M.D. lead the study alongside the URMC Vaccine Trials and Evaluation Unit (VTEU).
Remdesivir was developed by Gilead Sciences. It’s a broad-spectrum antiviral drug that has been tested in humans with the Ebola virus. Remdesivir has also been effective in treating illnesses caused by other coronaviruses like Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) in animals.
The trial is double-blind and placebo-controlled. Acute COVID-19 patients at Strong Memorial Hospital will be used in the study. In the future, the study may grow to include other antiviral treatments that the VTEU wants to test.
email@example.com / (585) 363-7031